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ABSTRACT
The emergence of multiple drug resistant (MDR) Acinetobacter baumannii has lead to an
increased interest in finding alternative antimicrobial compounds for controlling the pathogen.
The present study investigated the effect of three plant-derived antimicrobials, namely eugenol
(EUG), carvacrol (CAR), and thymol (THY), on A. baumannii biofilms. Using concentrations
equal to or greater than the minimum bactericidal concentration (MBC) of each compound, the
ability of EUG, CAR, and THY to inactivate the mature biofilms of three strains of MDR A.
baumannii on polystyrene microtiter plates and stainless steel coupons was examined. All three
plant-derived compounds significantly inactivated the bioflims of all three A. baumannii strains
tested (P < 0.05). After 10 min of incubation on polystyrene microtiter plates at 23°C, all three
compounds eliminated all viable biofilm-associated A. baumannii cells, reducing the biofilmassociated bacterial population by >7.0 log CFU/ml. Eugenol and CAR exerted a similar effect
at 37°C, while THY reduced the viable biofilm-associated bacterial population to 0.45 log
CFU/ml. On stainless steel coupons incubated at 23°C, all three compounds reduced the viable
biofilm-associated bacterial population by 6.5 log CFU/ml. Results indicate that EUG, CAR, and
THY could potentially be utilized to control biofilms of A. baumannii on abiotic surfaces, thus
preventing its persistence in the hospital environment. However, detailed follow up studies are
needed.
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INTRODUCTION
Acinetobacter baumannii is a Gram-negative, nosocomial pathogen (58). It has been
documented as the causative agent in cases of ventilator-associated pneumonia, wound infection,
urinary tract infection, and catheter-associated septicemia (5, 25). A. baumannii has also been
implicated in cases of endocarditis, osteomyelitis, and corneal perforation (66). In recent years,
A. baumannii has emerged as a prevalent nosocomial pathogen in military field hospitals in Iraq
and Afghanistan (57).
The emergence of multiple drug resistant (MDR) strains of A. baumannii constitutes a
significant public health threat. A. baumannii strains resistant to major classes of traditional
antibiotics including β-lactams, aminoglycosides, quinolones, tetracyclines and glycylcyclines,
polymyxins, trimethoprim-sulfamethoxazole, and chloramphenicol have been isolated (58). A
wide variety of mechanisms of antibiotic resistance have been identified in A. baumannii,
including drug-inactivating enzymes, efflux pumps, alteration in outer membrane proteins
(OMPs) and binding sites, and mechanisms of ribosomal protection (28, 58). The ability of A.
baumannii to rapidly acquire foreign genetic elements has contributed to the development of
multiple drug resistance in the bacterium (17, 31). The acquisition of mobile genetic elements
such as plasmids (18), transposons (70), and integrons (2, 18, 69, 71) has been reported.
The ability of A. baumannii to form biofilms also contributes to its pathogenesis. Biofilm
formation contributes to increased persistence in the hospital environment (58). A. baumannii
has been shown to survive for up to 26.5 days on desiccated abiotic surfaces (38). It has been
isolated from hospital suctioning equipment, washbasins, bed rails, bedside tables, ventilators,
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sinks, pillows, mattresses, and resuscitation equipment (65). A comprehensive literature review
conducted by Moultrie et al. (51) found that 73% of studies evaluated identified the environment
as the source of A.baumannii infection. A. baumannii strains which form substantial biofilms
have also been found to have greater resistance to both antibiotics (43, 64, 78) and disinfectants
(70).
Plant-derived essential oils are traditionally used as food additives, both to preserve foods
and enhance flavor (39). Components of several such essential oils include eugenol (EUG) and
trans-cinnamaldehyde found in clove and cinnamon leaf oils, respectively (23). Similarly,
carvacrol (CAR) and thymol (THY) are found in the oil from oregano (13) and thyme (74).
Previous studies have demonstrated the antimicrobial properties of several plant-derived
compounds. Eugenol, CAR, and THY have been shown to exert antimicrobial effects against the
Gram-negative bacteria Salmanella Enteritidis and Campylobacter jejuni (31). These plantderived compounds have also been shown to be effective against biofilm-associated bacterial
populations in particular. Carvacrol and THY have demonstrated the ability to inactivate the
biofilms of Staphylococcus aureus and Staphylococcus epidermidis (56), while EUG and CAR
have been shown to inactivate biofilms of Listeria monocytogenes and Escherichia coli O157:
H7 (59). However, no studies to our knowledge have been conducted to investigate the
antibacterial effects of these compounds on MDR A. baumannii. Therefore, the current study
was conducted to investigate the ability of EUG, CAR, and THY to inactivate mature A.
baumannii biofilms for potential use as disinfectants to reduce the persistence of A. baumannii
on abiotic surfaces.
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LITERATURE REVIEW
History
The current genus description and name Acinetobacter were first used in 1954 to
differentiate between motile and non-motile organisms of the genus Achromobacter (10, 58).
The designation was accepted more widely following the work of Baumann et al. in 1968 (4, 58).
A. baumannii was first identified through DNA-DNA hybridizations studies conducted by
Bouvet and Crimont in 1986 (9).
Biology
Acinetobacter spp. are gram-negative, aerobic, catalase-positive, oxidase-negative,
nonmotile, nonfermenting coccobacilli (58) which typically grow at 20-30°C on traditional
laboratory media (27). They are short gram-negative rods that are difficult to destain, leading to
possible misidentification as gram-negative or gram-positive cocci (58). Attempts to
phenotypically differentiate A. baumannii from other Acinetobacter spp. have proven ineffective
(31, 58). Acinetobacter genomic species 13TU, Acinetobacter genomic species 3, Acinetobacter
calcoaceticus, and A. baumannii are often referred to as either the A. calcoaceticus-A. baumannii
(ACB) complex or the A. baumannii-A. calcoaceticus (ABC) complex (57). Molecular methods
of differentiating these species are labor-intensive, expensive, and largely conducted only by a
few reference laboratories (58). The most accepted of these methods are DNA-DNA
hybridization (9), amplified 16S rRNA gene restriction analysis (ARDRA) (77), and highresolution fingerprint analysis by amplified fragment length polymorphism (AFLP) (37).
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Role as a Nosocomial Pathogen
A. baumannii poses a significant threat as a nosocomial pathogen. In survey studies from
75 countries, A. baumannii caused approximately 9% of ICU infections (81). It has been
implicated as the causative agent in cases of ventilator-associated pneumonia, wound infection,
urinary tract infection, and catheter-associated septicemia (5, 25). Less frequently, infections
have also resulted in meningitis, endocarditis, osteomyelitis, and corneal perforation (66).
Current data indicate that critically ill patients with ventilator-associated pneumonia and
bloodstream infections caused by A. baumannii experience increased mortality and prolonged
lengths of stay in the hospital (38).
Once present, A. baumannii is capable of persisting in the hospital environment for
extended periods. It has been isolated from hospital suctioning equipment, washbasins, bed rails,
bedside tables, ventilators, sinks, pillows, mattresses, and resuscitation equipment (65).
Persistent environmental contamination in the rooms of patients suffering Acinetobacter spp.
infections has been documented up to 13 days after discharge from the hospital (5). Jawad et al.
(38) showed that 22 strains of A. baumannii isolated from 8 hospital outbreaks in the German
metropolitan area were capable of surviving an average of 26.5 days on a desiccated abiotic
surface, namely glass cover slips. The hospital environment has been demonstrated as a mode of
transmission. A comprehensive literature review conducted by Moultrie et al. (51) found that
73% of studies evaluated identified the environment as the source of A.baumannii infection.
Hospital outbreaks have been traced back to various surfaces (5), including machinery used for
respiratory therapy (14), countertops (51), bedding (82), and improperly autoclaved reusable
needles (40). Martínez-Pellús et al. (49) identified environmental sources as frequent bacterial
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reservoirs of A. baumannii in a Spanish ICU. The study also reported frequent patient
colonization, as 35% had skin colonization, 43% had tracheal colonization, and 31% had rectal
colonization during their stay. Patient colonization can also contribute to further dissemination
of the pathogen through contact with healthcare providers. Morgan et al. (50) found that 20.5%
of healthcare worker interactions with patients in 6 different ICUs resulted in the contamination
of healthcare workers' gowns or gloves. MDR A. baumannii accounted for 32.9% of these
contaminations, the most abundant pathogen detected during the study. Healthcare workers
served as the source of infection in 36% of studies reviewed by Moultrie et al. (51). The
presence of A. baumannii in air samples collected from hospitals has also been reported. A
university hospital in Turkey identified 3 different genotypes of A. baumannii in air samples
from various locations throughout the facility (1). The fact that 1 of these genotypes was also
detected from clinical samples suggests that airborne transmission may contribute to infection.
A. baumannii in Modern Military Conflict
War wound infections by former Achromobacter spp. were first described as early as the
Korean War (47). In recent years, A. baumannii has emerged as a prevalent nosocomial
pathogen in military field hospitals in Iraq and Afghanistan (57). Approximately 14,000
American and British soldiers have been evacuated to medical facilities in their own countries
following wounds in Afghanistan and Iraq since 2001 (57). Consequently, the prevalence of A.
baumannii in domestic military medical facilities has increased as well. The United States
Centers for Disease Control and Prevention identified 102 cases of A. baumannii bloodstream
infections in 5 American military field medical facilities in Iraq and Afghanistan during the
period from 2002 to 2004, compared to 3 during the period from 2000 to 2002 (15, 57). Peterson
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et al. found that Acinetobacter spp. accounted for 36% of wound and blood stream infections in
trauma victims evacuated from Iraq to the naval hospital ship USNS Comfort during a study
period in 2003 (62). In a study of Acinetobacter spp. infection at the National Naval Medical
Center in Bethesda, MD, A. baumannii was isolated in 96% of cases (60).
Acinetobacter spp. are ubiquitous in the environment, commonly isolated from the soil,
water, and the skin and gastrointestinal tracts of healthy individuals (3, 28, 57). However, A.
baumannii has not been isolated from these environmental sources as frequently. Berlau et al.
(6) reported that, although 40% of healthy individuals had skin colonized with Acinetobacter
spp., only 1 of 192 individuals was found to have skin colonized with A. baumannii. Dijkshoorn
et al. (20) isolated A. baumannii from fecal samples in only 1% of healthy individuals examined
in the UK, and only 0.7% of healthy individuals examined in the Netherlands. In the case of
military personal in Iraq and Afghanistan, infection directly from these sources is unlikely to be a
significant factor (57, 60). Of 49 soil samples collected by Scott et al. (67) around 7 field
hospitals in Kuwait and Iraq, only 1 contained ABC complex. Murray et al. (52) cultured
samples from 61 open wounds in American military casualties immediately upon arrival at a
field hospital in Baghdad, none of which were colonized with A. baumannii, and only 3 of which
were colonized with any Acinetobacter spp. Current evidence suggests that non-U.S. personnel
admitted to U.S. military field medical facilities have served as a reservoir for ABC complex
(57). From November 2006 to October 2007, 97.5% of patients in an American Army combat
hospital in Baghdad from which A. baumannii was isolated were Iraqi natives (33). From
September 2007 to August 2008, 91% of patients positive for multi-drug resistant (MDR) Gramnegative bacteria at the largest U.S. military field hospital in Afghanistan were Afghan (72).
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MDR Acinetobacter spp., including A. baumannii, accounted for 20% of these samples, making
it the second most common group of MDR Gram-negative bacteria isolated.
Emergence of Antibiotic Resistance
Emergence of MDR A. baumannii in recent years constitutes a significant public health
threat. Definitions of multiple drug resistance vary across regions of the world and different
epidemiological studies (58). Peleg et al. (58) defined multiple drug resistance as resistance to 3
or more of the following five drug classes: antipseudomonal cephalosporins, antipseudomonal
carbapenems, ampicillin-sulbactam, fluoroquinolones, and aminoglycosides. Strains of A.
baumannii have shown resistance to β-lactams, aminoglycosides, quinolones, tetracyclines and
glycylcyclines, polymyxins, trimethoprim-sulfamethoxazole, and chloramphenicol (58). In a
study of 102 A. baumannii strains isolated from infections in service members injured in Iraq,
Kuwait, and Afghanistan, a significant amount of antimicrobial resistance was found, including
resistance to all drugs tested found in 4% of isolates (15, 28). Jawad et al. (38) investigated the
susceptibility of A. baumannii strains isolated from 8 hospital outbreaks to several
antimicrobials. These susceptibilities were also compared to sporadic strains. They found that
outbreak strains were significantly more resistant to aminoglycosides, amoxicillin-clavulanate,
mezlocdillin, cefepime, cetriaxone, cefotaxime, and ciproflaxacin than sporadic strains.
Currently utilized antimicrobial treatments for MDR A. baumannii include the aminoglycosides
amikacin and tobramycin, polymixin E (colistin) and polymixin B, tigecycline, the tetracyclines
minocycline and doxycycline, and a combination of the β-lactamase inhibitor sulbactam and the
β-lactam ampicillin (26). A combination therapy including multiple antimicrobials is usually
required to successfully treat MDR A. baumannii infections (5).
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Mechanisms of Antibiotic Resistance
A. baumannii has acquired a wide variety of antibiotic resistance mechanisms, including
drug-inactivating enzymes, efflux pumps, alteration in outer membrane proteins (OMPs) and
binding sites, and mechanisms of ribosomal protection (28, 58). It produces a wide variety of βlactamases, both chromosomally and plasmid mediated (7), including chromosomally encoded
AmpC cephalosporinases, referred to as Acinetobacter-derived cephalosporinases (ADCs) (8,
58) and both narrow-spectrum β-lactamases (NSBLs) (79) and extended-spectrum β-lactamases
(ESBLs) (54, 62). Carbapenemases, including serine oxacillinases (OXAs) and metallo-βlactamases (MBLs) (63) pose particular difficulty to treatment (59). Multidrug efflux pumps,
such as AdeABC and AbeM (48, 58, 70), function against β-lactams, aminoglycosides,
quinolones, and tetracyclines and glycyclines (79). Tetracycline-specific efflux pumps have also
been identified (33). Alterations in many OMPs have been associated with increased resistance
to β-lactams (58). The decreased expression or loss of such OMPs as at 22kDa (7), 29 kDa
(CarO) (46, 54), and 33-36 kDA (17) have been implicated in carbapenem reistance. Resistance
to quinolones has been attributed to mutations in gyrA and parC leading to altered binding sites
on topoisomerase IV and DNA gyrase (35, 80). Decreased affinity or expression of penecillinbinding proteins (PBPs) has further contributed to β-lactam resistance (31, 58). Ribosomal
protection mechanisms mediated by tetM and tetO have been identified in tetracycline-reistant
strains (18), as well as in strains with16S rRNA methylation leading to aminoglycoside
resistance (3).
The acquisition of foreign genetics by A. baumannii has contributed to the development
of multi-drug resistance (18). A. baumannii is extremely capable of rapidly acquiring
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antimicrobial-resistance genes (31) via mobile genetic elements including plasmids (18),
transposons (70), and integrons (2, 18, 69, 71). While examining the genetics of the 86-kb
resistance island AbaR1 found in an epidemic strain of A. baumannii isolated in France, Fournier
et al. (28) predicted that 82 of 88 open reading frames originated from other Gram-negative
bacteria, including Pseudomonas spp., Salmonella spp., and E. coli. (27, 58). Class I and class II
integrons have been associated with multiple-antibiotic resistance among nosocomial isolates (2,
18, 28, 70). Poirel et al. (63) found that 7 clonally related isolates of A. baumannii recovered
from Valenciennes Hospital in France contained a gene encoding the Ambler class A ESBL
VEB-1 on a class I integron previously identified only in Pseudomonas aeruginosa isolates
recovered in Southeast Asia. Although data regarding the natural competency of A.baumannii is
lacking (58), other Acinetobacter spp. have shown a high frequency of natural transformation,
including Acinetobacter spp. BD413 (58).
Biofilm Formation
One of the characteristics of A. baumanii which contributes to its extended survival in the
environment is its ability to form bioflims, or communities of intercommunicating bacterial cells
associated with a surface and encased in an extracellular matrix of carbohydrates, nucleic acids,
proteins, and other macromolecules (29, 72). Tomaras et al. (75) described the processes
involved in the surface attachment and biofilm formation on polystyrene and polypropylene
utilizing the strain 19606. After inoculating petri dishes and Teflon strips and incubating them at
room temperature for 10-15 minutes, they found a high level of adherence to these surfaces after
washing with tap water. Overnight incubation in Luria-Bertani (LB) broth at 37°C in both
polystyrene tubes and square petri dishes also resulted in adherence. They noted that the densest
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cell aggregates formed at the liquid-air interface of the culture, and grew upward onto the walls
of the containers. At this interface, channels in between stacks of cells were observed, which
would allow for the acquisition of nutrients and removal of waste. Light microscopy of cells
attached to the bottom surface of petri dishes revealed discrete cell clumps rather than a
monolayer, even after several days of incubation. Areas without cells were also found within
cellular aggregates, as has also been described in P. aeruginosa (43). Fluorescence microscopy
also identified the presence of exopolysaccharides, present between cell stacks as well as
covering the top later of cells above the broth.
A variety of factors contributing to biofilm formation in A. baumannii have been
identified. Tomaras et al. (75) found that cells were linked through pili-like extracellular
appendages. Genetic analysis of a mutant strain in the same study revealed that the absence of a
protein very similar to that encoded by the Vibrio parahemolyticus csuE gene resulted in an
inability to form surface pilli and a subsequent inability to form substantial cell clusters,
characteristics which were restored upon reintroduction of the csuE-like gene. This pilli
formation likely contributes to the initial steps of biofilm formation by allowing bacterial cells to
adhere to abiotic surfaces and initiate the formation of microcolonies that continue to fully
develop into bioflims. The abal autoinducer synthase gene A. baumannii has been shown to
produce the signaling molecule acyl-homoserine lactone (AHL), a molecule which regulates
quorum sensing (29). Niu et al. (55) reported that mutants of the M2 strain which lacked abal
failed to produce AHL and had subsequent decreases in biofilm formation of 30-40%. Biofilmforming capabilities were restored upon the addition of purified M2 AHL, indicating the
importance of cellular communication to biofilm maturation in A. baumannii, as with other
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prominent bacterial pathogens (29). Loehfelm et al. (47) found that the absence of a homolog to
the 854 kDa staphylococcal biofilm-associated protein (Bap), identified in A. baumannii strain
307-029 and conserved across 98 strains, resulted in an inability to maintain volume and
thickness of mature biofilms, suggesting that Bap supports the structure of mature biofilms. Choi
et al. (16) determined that the cell-associated polysaccharide poly-beta-(1,6)-Nacetylglucosamine (PNAG), regulated by the pgaABCD locus, contributed to the biofilm
phenotype of 30 clinical isolates of A. baumannii. Mutant strains with a pga locus deletion lost
PNAG production and experienced subsequent loss of the strong biofilm phenotype, which was
restored through complementation.
Biofilm formation can vary noticeably across different strains of A. baumannii (70).
When examining 2 different strains isolated from the same patient, one mucoid and highly
virulent in a mouse pneumonia model (AB-M) and the other non-mucoid and moderately
virulent in the same model (AB-NM), Kempf et al. (41) found that the AB-NM strain had cells
with rougher surfaces formed in larger clusters, while the AB-M strain had smooth cell surfaces
and formed smaller clusters. Calcofluor white staining showed that the AB-NM strain formed
more biofilm than the AB-M strain, resulting in 40 times more adherence to silicone catheter
material. Strong biofilm formation has been identified in clinical isolates associated with catherrelated urinary tract infections, wound infections, septicemia, and shunt-related meningitis (28,
70).
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Biofilm Formation and Antimicrobial Resistance
Biofilm formation in A. baumannii has been correlated its to increased antimicrobial
resistance (78). Vidal et al. (78) examined the effects of biofilm formation on the efficacy of
sulbactam and imipenem. While both antibiotics were strongly bactericidal against young
biofilms, the efficacy of sulbactam was significantly reduced in aged biofilms and the efficacy of
imipenem was reduced to some extent. Rao et al. (64) found that biofilm-producing A. baumanii
strains had comparatively higher resistance to amikacin, cephotaxime, ciproflaxacin, and
aztreonam than non-biofilm-forming strains. Lee et al. (43) found that isolates which had the
blaPER-1 gene coding for the blaPER-1 ESBL had greater capacity for biofilm formation than
strains which lacked the gene. Studying clinical strains of A. baumannii isolated from 2 Ohio
hospitals, Srinivasan et al. (70) found that surface disinfectants, such as benzalkonium chloride,
chlorhexidine gluconate, and Virkon-S were significantly less effective against strains which
produced strong biofilms compared to those which produced weak biofilms.
Plant-Derived Antimicrobial Compounds
Plant-derived essential oils are a group of natural antimicrobials that are traditionally
used as food additives, both to preserve foods and enhance flavor (39). This study utilized three
such compounds with previously demonstrated antimicrobial properties, including eugenol
(EUG), carvacrol (CAR), and thymol (THY). All these plant-derived molecules are classified as
generally recognized as safe (GRAS) by the United States Food and Drug Administration (EUG:
21CFR582.60; CAR and THY: 21CFR172.515) (39).
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Eugenol (4-Allyl-2-methoxyphenol) is a colorless liquid phenol with the chemical
formula C10H12O2 (22, 23). It is a component of clove oil, isolated via extraction in hydroxide
solutions and subsequent distillation (23). Eugenol is currently used as a food flavoring,
analgesic in dental medicine, and production of synthetic vanillin (23).
Carvacrol (5-Isopropyl-2-methylphenol) is a colorless to yellowish liquid phenol with the
chemical formula C10H14O (12, 13). It is a major component of the essential oils of various
plants, chiefly oregano (13). It is also produced synthetically from p-cymene (13).
Thymol (2-Isopropyl-5-methylphenol) is a crystalline phenolic compound also of the
chemical formula C10H14O (73, 74). It is a major component of the essential oil of Origanum,
like CAR, as well as thyme (74). It is also produced synthetically from p-cymene, piperitone, or
m-cresol (74).
The antimicrobial effects of these three plant-derived molecules have been reported. Our
laboratory previously investigated the antibacterial effects of EUG, CAR, and THY on 2 Gramnegative bacteria, namely S. Enteritidis and C. jejuni, in chicken cecal contents in vitro (31).
Eugenol and CAR reduced S. Enteritidis by >5.0 log10 cfu/mL while THY, although the least
effective of the 3 molecules, also showed a concentration-dependent reduction. All
concentrations of CAR (10, 20, and 30 mM), the 2 higher concentrations of EUG (20 and 30
mM), and the highest concentration of THY (30 mM) reduced C. jejuni to undetectable levels 15
seconds after addition of the molecules. The antimicrobial effects of these compounds with
particular focus on the inactivation of biofilms have also been reported. Nostro et al. (56)
examined the effects of CAR and THY on biofilms produced by 6 strains of S. aureus and S.
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epidermidis. At high concentrations, ranging from 0.125% to 0.5% depending on the strain, both
molecules were capable of completely inactivating the biofilms of both bacteria. Pérez-Conesa et
al. (59) investigated the effects of EUG and CAR (encapsulated in non-ionic surfactant solution)
on biofilms formed by L. monocytogenes and E. coli O157: H7 on polycarbonate membranes.
Although E. coli O157:H7 strains were more susceptible to both compounds than L.
monocytogenes strains, inactivation of colony biofilm was observed in each. Three of the 4 E.
coli O157:H7 strains had viable cell numbers decreased below detectable levels after 3 hours of
treatment with the molecules. The effect on L. monocytogenes varied more across strains, and 2
of the 4 strains were more susceptible to CAR than EUG. However, both showed excellent
potential for inactivation of biofilm produced by these two bacteria.
The availability of new, more effective methods to inactivate A. baumanii biofilms could
significantly contribute to the control of this increasingly threatening nosocomial pathogen,
reducing its persistence in hospital environments. The objective of this study was to investigate
the efficacy of EUG, CAR, and THY in inactivating mature biofilms of A. baumannii at 23 and
37°C on polystyrene microtiter plates, as well as at 23°C on stainless steel coupons.

MATERIALS AND METHODS
Bacterial strains, media, and plant-derived molecules. Three strains of A. baumannii
(173795B, 474030, and 260177B) were used for in this study. All strains of A. baumannii were
kindly provided by Daryl Hoban, International Health Management Associates (IHMA),
Schaumburg, IL, USA. All bacteriological media used were obtained from Difco (Difco, BD,
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Sparks, MD). Each strain was cultured separately in 10 ml of sterile tryptic soy broth (TSB) in
30 ml screw-cap tubes at 37°C for 24 h with agitation (150 rpm). Following incubation, the
cultures were sedimented by centrifugation (8,000 x g for 10 min), washed twice, and
resuspended in 10 ml of sterile phosphate-buffered saline (PBS), pH 7.2. The bacterial
population in each culture was determined by plating 0.1 ml portions of diluted culture on
duplicate tryptic soy agar (TSA) plates and incubated at 37°C for 24 h. The efficacy of EUG,
CAR, and THY (Sigma Chemical Co., St. Louis, MO) for inactivating A. baumannii biofilm was
investigated on polystyrene microtiter plates and stainless steel coupons..
Inactivation of A. baumannii biofilm by EUG, CAR, and THY. EUG, CAR, and THY
levels used in this experiment were equal to or greater than minimum bactericidal concentrations
(MBCs) of the molecules, the minimum concentration at which A. baumannii is killed. The
MBCs (EUG: 0.2%; CAR and THY: 0.075%) were selected based on preliminary experiments
conducted in our laboratory.
Preparation of Media. Tryptic soy broth (pH 7.0) and TSA were prepared according to
the manufacturer's directions. Glass beads (435 to 600 µm in diameter; Sigma-Aldrich) were
added to PBS to facilitate removal of adherent A. baumannii cells from the surfaces of stainless
steel coupons.
Inactivation of A. baumannii biofilm on microtiter plates. A. baumannii strains were
grown to stationary phase in TSB at 37°C for 24 h. The cultures were separately centrifuged
(8,000 x g for 10 min), resuspended in TSB. 200 µl of washed culture was used as inoculum
(~6.0 log CFU). Sterile 96-well polystyrene tissue culture plates (Falcon, Franklin Lakes, NJ)
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were inoculated with 200 µl of the cell suspension and allowed to incubate at 23 or 37°C for 24 h
without agitation to facilitate biofilm formation. The antibiofilm effect of 0.2%, 0.5%, and
0.75% EUG, 0.075% and 0.15%, and 0.3% CAR or THY was tested with an exposure time of 0,
2, 5, and 10 min. The surviving bacterial population in the biofilm was enumerated by scraping
and plating the biofilm on duplicate TSA plates. Triplicate samples were included for each
treatment, and the experiment was replicated two times.
Inactivation of A. baumannii biofilm on stainless steel coupons. Stainless steel
coupons (type 304; 5 by 2 cm; surface area, 20 cm2) with no. 4 finish were used. A. baumannii
strains separately grown to stationary phase in TSB at 37°C for 24 h were centrifuged (8,000 x g
for 10 min), and cells were resuspended in 40 ml TSB (~6.0 log CFU). A volume of one ml of
the resuspended culture (~6.0 log CFU) was used as the inoculum in 12-well cell culture plates
(Falcon, Franklin Lakes, NJ). The coupons described before were deposited separately into
wells containing inoculum and incubated at 23°C for 24 h without agitation for biofilm
formation. The coupons were gently washed in 1 ml sterile PBS three times and resuspended in
1 ml of TSB. The antibiofilm effect of 0.2% and 0.75% EUG, and 0.075% and 0.3% CAR or
THY was tested with an exposure time of 0, 2, 5, and 10 min. The coupons were then transferred
to 50 ml centrifuge tubes containing 2 ml PBS and 1g glass beads. The tubes were vortexed for
5s. The PBS suspension was serially diluted in PBS, surface plated (0.1 ml) on TSA, and
incubated at 37°C for 24 h. A. baumannii colonies formed on the plates were then enumerated.
Triplicate samples were included for each treatment, and the experiment was replicated two
times.
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Statistical Analysis. Data from the four independent replicate experiments were pooled.
The effect of different concentrations of EUG, CAR and THY, sampling time, temperature and
their interaction on bacterial counts was analyzed using PROC MIXED of SAS (SAS Institute,
Cary, NC, U.S.A.). Variation among replicates was used as the error term. Data were expressed
as least squares means; differences were considered significant at P < 0.05.

RESULTS
Since EUG, CAR, and THY were found to be equally effective in inactivating all the
three strains of A. baumannii, only the results obtained from 173795B strain are presented here.
The efficacy of EUG, CAR and THY for inactivating fully formed A. baumannii biofilms on
polystyrene microtiter plates at 23 and 37°C is depicted in Figures 1 to 6. The mean biofilmassociated population of control samples without any antimicrobial at 23 and 37°C were ~7.4 log
CFU/ml and 7.7 log CFU/ml, respectively. At both 23 and 37°C, 0.75% EUG eliminated all
viable cells in the biofilm after 10 min of incubation, as did 0.3% CAR and 0.3% THY after 10
min of incubation at 23°C.

Since there was no difference in the antibiofilm effect of the

molecules between the two temperatures at which A. baumannii biofilms were grown (P < 0.05),
only the results obtained from A. baumannii biofilms grown at 23°C are described here. The
antibiofilm effect of the molecules was both time-dependent and concentration-dependent (P <
0.05). The bacterial population in control samples did not change during the 10 min interval.
Eugenol at 0.2%, 0.5%, and 0.75% reduced the biofilm-associated A. baumannii population to
~1.8 log CFU/ml, 0.3 log CFU/ml, and undetectable levels immediately after addition of the
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molecule, respectively. After 2 min of incubation with the molecule, 0.2% EUG reduced the
biofilm-associated A. baumannii population to ~0.9 log CFU/ml, while 0.5% and 0.75% EUG
eliminated all viable A. baumannii cells. After 10 min of incubation with the molecule, 0.2%
EUG had also eliminated all viable A. baumannii cells from the biofilm-associated population.
Antibiofilm effects of CAR and THY were also both time and concentration-dependent (P <
0.05). However, only 0.3% CAR or THY eliminated all viable cells of A. baumannii biofilm.
Carvacrol at 0.075% and 0.15% decreased the biofilm-associated A. baumannii population to
~1.8 and ~ 1.2 log CFU/ml after 10 min of incubation, respectively. Similarly, thymol at 0.075%
and 0.15% reduced the biofilm-associated A. baumannii population to ~0.6 and 0.3 log CFU/ml
after 10 min of incubation, respectively.
The effect of EUG, CAR, and THY for inactivating A. baumannii biofilms on stainless
steel coupons incubated at 23°C is depicted in Figures 7 to 9. The antibiofilm effect of the
compounds was not dependent on the time in which the sample was incubated with the molecule
or their concentration (P > 0.05). The average initial bacterial population in the control samples
was ~7.0 log CFU/ml. The treatment with all concentrations of EUG, CAR, and THY reduced
the bacterial population to ~0.9 log CFU/ml immediately after the addition of the molecule.

DISCUSSION
The emergence of MDR A. baumannii constitutes a significant public health threat. The
ability of the pathogen to resist dessication and form biofilms allows it to survive for long
periods of time on abiotic surfaces (58). Subsequently, nosocomial infections resulting in
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ventilator-associated pneumonia, wound infection, urinary tract infection, and catheterassociated septicemia have been reported (5, 25). Difficulty controlling MDR A. baumannii with
traditional classes of antibiotics and disinfectants has increased interest in investigating novel
antimicrobial compounds to which the pathogen is susceptible. The current study investigated
the efficacy of plant-derived compounds in inactivating the mature biofilms of MDR A.
baumannii.
Bacterial inactivation by EUG, CAR, and THY has been attributed to their
hydrophobicity, which allows them to increase permeability through disrputing the structure of
lipids in the bacterial cell and mitochondrial membranes (11). In addition, the hydroxyl group on
EUG is thought to bind to proteins, preventing enzymatic action (81). CAR has also been shown
to weaken the proton motive force, leading to a subsequent decrease in intracellular ATP (75).
In conclusion, the plant-derived molecules EUG, CAR, and THY were effective in
inactivating mature A. baumannii biofilms on polystyrene microtiter plates and stainless steel
coupons. These results suggest that EUG, CAR, and THY could be potentially used as
antimicrobials to inactivate A. baumannii biofilms in hospital settings, preventing persistence,
transmission, and subsequent infection of the pathogen. However, detailed follow up studies are
needed.
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FIGURES

FIGURE 1. Inacvitation of A. baumannii 173795B biofilm by EUG on polystyrene microtiter
plates at 23°C.

FIGURE 2. Inacvitation of A. baumannii 173795B biofilm by EUG on polystyrene microtiter
plates at 37°C.
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FIGURE 3. Inacvitation of A. baumannii 173795B biofilm by CAR on polystyrene microtiter
plates at 23°C.

FIGURE 4. Inacvitation of A. baumannii 173795B biofilm by CAR on polystyrene microtiter
plates at 37°C.
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FIGURE 5. Inacvitation of A. baumannii 173795B biofilm by THY on polystyrene microtiter
plates at 23°C.

FIGURE 6. Inacvitation of A. baumannii 173795B biofilm by THY on polystyrene microtiter
plates at 37°C.
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FIGURE 7. Inacvitation of A. baumannii 173795B biofilm by EUG on stainless steel coupons at
23°C.

FIGURE 8. Inactivation of A. baumannii 173795B biofilm by CAR on stainless steel coupons at
23°C.
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FIGURE 9. Inactivation of A. baumanii 173795B biofilm by THY on stainless steel coupons at
23°C.

